Johnson & Johnson announced that its single-dose vaccine provided strong protection against moderate to severe COVID-19. Preliminary results show that the vaccine had an overall effectiveness of 66 percent against moderate to severe infection 28 days after vaccination.
Healthline Daily News Healthline Daily News

The Latest on COVID-19

Updated on January 29, 2021 at 3:00 p.m. PDT
  • Johnson & Johnson announced that its single-dose vaccine provided strong protection against moderate to severe COVID-19. Preliminary results show that the vaccine had an overall effectiveness of 66 percent against moderate to severe infection 28 days after vaccination.
  • Severe cases of COVID-19 might influence the quality of sperm, possibly reducing fertility, according to a new study published on Thursday, Jan. 28, in the journal Reproduction.
  • The European Union (E.U.) has approved the AstraZeneca COVID-19 vaccine. The E.U. will halt the transportation of any of this vaccine outside of E.U. borders until AstraZeneca has met its supplier obligations, according to the New York Times.
Read the full update
COVID-19 Caution: Even With Vaccines, It May Be Too Early to Have Small Gatherings Again
COVID-19 Caution: Even With Vaccines, It May Be Too Early to Have Small Gatherings Again
Experts say that even with COVID-19 vaccines being distributed, it’s still too early to gather safely in small groups.
Read on
If You’re Young or Healthy, You May Need to Wait Until Summer for COVID-19 Vaccine
If You’re Young or Healthy, You May Need to Wait Until Summer for COVID-19 Vaccine
READ ON Read on
Does Intermittent Fasting Work, and How Can You Do It? What to Know
Does Intermittent Fasting Work, and How Can You Do It? What to Know
READ ON Read on
9 Fitness Trends to Expect in 2021
TREND REPORT
9 Fitness Trends to Expect in 2021
GO NOW Read on
Johnson & Johnson’s COVID-19 Vaccine Is 66% Effective Overall, Over 50% on Emerging Variants
Johnson & Johnson’s COVID-19 Vaccine Is 66% Effective Overall, Over 50% on Emerging Variants
READ ON Read on
Novavax COVID-19 Vaccine 90% Effective, 60% Against South African Variant
Novavax COVID-19 Vaccine 90% Effective, 60% Against South African Variant
READ ON Read on
More Top Reads
View in browser
Did a friend send you this email? Subscribe here.
To see all newsletters, click here.
Privacy Policy|Unsubscribe|Get this email less often
© 2021 Healthline Media
660 3rd Street, San Francisco, CA 94107